LILRA5 (leukocyte immunoglobulin-like receptor A5) is an inhibitory immune receptor that plays a crucial role in regulating inflammatory responses and innate immunity. The receptor is primarily expressed in neutrophils, macrophages, and endothelial cells, with particularly high expression in activated macrophages during early sepsis 12. LILRA5 functions as an immunosuppressive regulator that negatively controls immune responses by inhibiting proinflammatory cytokine production, including interleukin-12 and interleukin-13, while promoting anti-inflammatory mediators like interleukin-10 1. The receptor demonstrates protective effects in multiple disease contexts - it shows cardioprotective properties in nonischemic cardiomyopathy with decreased expression associated with various cardiomyopathy subtypes 3, and serves as a diagnostic biomarker for sepsis with high accuracy (AUC 0.875-0.980) 4. LILRA5 deficiency exacerbates pathological conditions, as demonstrated in bacterial keratitis models where knockout mice showed increased proinflammatory cytokine production and more severe infection outcomes 1. The receptor is also linked to oxidative stress regulation, with LILRA5+ macrophages exhibiting the highest oxidative activity in sepsis 2. Clinically, LILRA5 represents a potential therapeutic target, with several small molecules identified that can modulate its expression and function 34.